Tocilizumab (Actemra) and Medicare

The short answer

Yes, Medicare covers tocilizumab both ways. Which part of Medicare pays, and how much you pay, depends entirely on how you get it.

• The shot you give yourself at home is covered by your Part D drug plan. Your costs are capped: in 2026 you cannot pay more than $2,100 for the whole year, no matter what.
• The infusion at a clinic is covered by Part B. You pay 20% of the cost, and there is no yearly ceiling at all — around $6,700 a year — unless you have a Medicare supplement policy, in which case it may cost you almost nothing.

So the cheaper route depends on what other coverage you have. That is the whole decision, and it is worth ten minutes of your time.

The two forms, side by side

Infusion figures use Medicare’s published payment rate for tocilizumab and the approved giant cell arteritis dose of 6 mg per kilogram every four weeks, for an adult of about 70–80 kg. Your dose and your weight change the number. The infusion also has a separate charge for the visit itself, which is extra.

Which one is cheaper for you

This flipped recently and a lot of advice online has not caught up. Before 2025 there was no ceiling on Part D either, and the shot could be brutally expensive. The Inflation Reduction Act put a hard cap on Part D — $2,000 in 2025, $2,100 in 2026, $2,400 in 2027 — and left Part B untouched.

• If you have Original Medicare and no supplement, the shot is dramatically cheaper. $2,100 versus around $6,700, and the $6,700 has no upper limit if your dose or weight is higher.
• If you have a Medicare supplement policy, it flips. The supplement covers the 20% on the infusion, so the infusion may cost you almost nothing, while the shot still runs you $2,100 through the drug plan.
• If you have Medicare Advantage, the plan sets its own charges for the infusion — either 20% or a flat amount capped at $340 per treatment — and everything stops at the plan’s yearly limit. But see the section on approvals below, because with Advantage the price is not the main issue.
• If you have Medicaid as well as Medicare, or you qualify for a Medicare Savings Program, most of this disappears. Ask.

Whether the shot or the infusion is right for you is a medical question, not a money one. Both are FDA-approved for giant cell arteritis. But if cost is the only thing pushing you one way, tell your rheumatologist. It may be an easy problem to solve.

Nobody has to approve the infusion — under Original Medicare

If you are on Original Medicare and you get tocilizumab as an infusion in a doctor’s office or clinic, there is no prior authorization. Nothing to submit, nothing to wait for, and nobody can require you to fail a cheaper medication first. Original Medicare is not permitted to do either of those things.

Medicare Advantage plans are permitted to do both, and routinely do. Since 2019 they have been allowed to apply step therapy to medications given in a clinic. Real 2026 Advantage policies require patients to try a biosimilar version first before they will pay for Actemra itself.

The shot always needs approval, whichever kind of Medicare you have. In the drug plan formularies CMS published for 2026, tocilizumab 162 mg required prior authorization on every single plan that covered it, and about four in five put it on the specialty tier. That is not a reason to pick one drug plan over another — it is universal. It is a reason to start the paperwork early and never assume a renewal is automatic.

How long the approval actually takes

There is published evidence on this, and it is worth knowing before you are in the middle of it. A 2025 study in the Journal of Rheumatology followed 82 patients with giant cell arteritis at a single center. Prior authorization was required for 96% of them. The average time from the request being submitted to the first dose actually reaching the patient was 43 days — about 17 days to get approved, then another 30 days before treatment started.

A disclosure: I am one of the authors of that study. It came out of our own clinic, which is why the number is on this page — we measured it because we kept watching it happen. PubMed

To be clear about what that does and does not mean: giant cell arteritis is treated urgently with steroids, and steroids are what protect your vision. Tocilizumab is added to bring the steroid dose down. So a delay in getting tocilizumab approved is not the same as going untreated — but it does mean longer on a higher steroid dose, with everything that comes with that.

The practical version: ask the office to start the paperwork the day it is decided, ask them to tell you if anything is denied, and appeal if it is. Across Medicare Advantage in 2024, only about one denial in nine was ever appealed — and 81% of the appeals that were filed succeeded.

There are now three cheaper versions

Tocilizumab has biosimilars — the same medicine made by a different company, approved by the FDA on the same evidence standard. All three are approved for giant cell arteritis:

• Tyenne (tocilizumab-aazg) — infusion and self-injection. About 25% cheaper than Actemra at Medicare’s rate, which makes it the biggest saving of the three on your 20%.
• Avtozma (tocilizumab-anoh) — infusion and self-injection.
• Tofidence (tocilizumab-bavi) — infusion only.

Two things to know. None of them is legally “interchangeable,” which means a pharmacy cannot swap one for another on its own — your doctor has to prescribe the specific one. And your plan decides which one it covers, so the version your plan wants is not always the version your infusion center stocks. If your plan makes you switch, ask the office to confirm the exact product before your next appointment.

If you are on the infusion and paying 20% of it, asking about the biosimilar is the single easiest way to lower that number. It is worth raising.

Things that surprise people

• The whole $2,100 lands in January. At a weekly dose you hit the cap on the first or second fill of the year. Medicare has a program that spreads it across twelve months instead, interest-free — about $175 a month — but you have to sign up for it. It is called the Medicare Prescription Payment Plan.
• Manufacturer copay cards do not work if you have Medicare. Federal law prohibits it, and that includes Medicare Advantage and Medigap. It is not your plan being difficult. What can help is the manufacturer’s patient assistance foundation, which is a different thing and does cover people on Medicare, and independent charitable foundations that help with cost-sharing.
• Where you get infused changes the price. A hospital outpatient department often costs you more than a doctor’s office or a home infusion for the identical medication. If your 20% feels higher than it should, this is often why.
• Approval expires. Plans approve expensive medications for a set period, usually a year. January is when plans change what they cover — if a letter arrives about your coverage changing, act on it that week rather than waiting for the pharmacy to say no.
• Extra Help. If your income is modest, Extra Help can reduce Part D costs to nearly nothing. The income limits are higher than most people assume and it is badly underused.

Free help, from someone who is not paid a commission

Before you talk to anyone who advertises Medicare plans, talk to a state counselor. It is free, federally funded, and they earn nothing whichever plan you pick.

• Washington: SHIBA — insurance.wa.gov/shiba or 1-800-562-6900
• Any other state: SHIP — shiphelp.org
• Check your plan’s drug list — medicare.gov/plan-compare
• Spread the January cost — medicare.gov/prescription-payment-plan
• Extra Help — ssa.gov/medicare/part-d-extra-help

Why isn’t my infusion covered by the $2,100 cap?

Because the $2,100 cap only applies to Part D, and an infusion is paid by Part B. The cap Congress created covers drugs you pick up and take yourself. A medication a nurse or doctor gives you is paid under Part B instead, where you owe 20% of the cost every time and there is no annual ceiling at all.

It is the same Medicare, often the same drug, and frequently the same disease. The rulebook is chosen by who puts the medicine in you. Almost everything written about the cap leaves this out, so people on infusions read that their costs are now limited, and then the bills keep coming.

A worked example. If Medicare’s approved amount for a year of your infusions is $18,000, you owe about $3,600 — this year, next year, and every year you stay on it. The $2,100 cap does not apply to any of it.

Four things do put a ceiling on Part B costs:

• A Medicare supplement (Medigap) policy, which pays the 20% for you. This is the main one, and the window to buy one closes six months after you enroll in Part B in most states.
• A Medicare Advantage plan’s yearly out-of-pocket maximum, which applies to everything the plan covers — though it comes with prior authorization attached.
• QMB, a Medicare Savings Program that eliminates the 20% entirely. This is the one people are not told about — and note that Extra Help, which people are told about, does nothing for a Part B drug.
• Full Medicaid, or retiree coverage that pays after Medicare.

Related

• Medicare and your medication — look up any other medication and compare your coverage options
• Giant cell arteritis fast track
• All patient resources
• Where you get infused changes the bill — the same infusion costs more at a hospital, and the bill nobody warns you about

Where these figures come from

1. Actemra prescribing information, revised December 2025 — FDA. Giant cell arteritis dosing: 162 mg subcutaneously weekly, or every other week based on clinical considerations; 6 mg/kg intravenously every four weeks. Both routes are FDA-approved for giant cell arteritis.
2. Medicare payment limit for tocilizumab (HCPCS J3262): $5.408 per mg, CMS Part B ASP pricing file effective July 1 – September 30, 2026.
3. Actemra 162 mg wholesale acquisition cost of $1,174.81 per syringe or ACTPen, effective January 6, 2026 — Genentech published price list.
4. Part D annual out-of-pocket cap of $2,100 and deductible of $615 for 2026 — CMS Final CY2026 Part D Redesign Program Instructions. Cap established by the Inflation Reduction Act of 2022. The 2027 cap is $2,400.
5. Part B annual deductible of $283 and 20% coinsurance with no annual limit for 2026 — CMS, “2026 Medicare Parts A & B Premiums and Deductibles,” November 2025; Social Security Act §1833(a).
6. Prior authorization and step therapy permitted for Medicare Advantage Part B drugs since 2019, and not permitted in Original Medicare — CMS, “Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs”; 42 CFR §422.136.
7. Prior authorization required on 100% of 2026 Part D formularies covering tocilizumab 162 mg, specialty tier on approximately 79% — analysis of the CMS Prescription Drug Plan Formulary File, July 2026 release.
8. Time from prior authorization request to first tocilizumab dose in giant cell arteritis (mean 43 days; prior authorization required in 96% of cases) — Feterman Jimenez D, Thomason JL, Liew JW, Ferguson S, Hughes G, Bays AM, Journal of Rheumatology, 2025. PMID 40089304. The author of this page is a co-author of this study.
9. Medicare Advantage appeal rates and outcomes for 2024 (11.5% of denials appealed, 80.7% of appeals overturned) — KFF analysis of CMS data, 2026.
10. Tocilizumab biosimilars, indications and payment limits — FDA biosimilar product information; CMS Part B ASP pricing file, July 2026 (Tofidence Q5133, Tyenne Q5135, Avtozma Q5156).
11. Prohibition on manufacturer copay assistance for federal healthcare program beneficiaries — federal Anti-Kickback Statute, 42 U.S.C. §1320a-7b.
12. Medicare Prescription Payment Plan — CMS, medicare.gov/prescription-payment-plan.

One honest caveat about the infusion figure: whether a self-injection given in a clinic rather than at home is billed to Part B varies by region, because each Medicare contractor keeps its own list of drugs it considers self-administered. If you get your shot at the office rather than at home, ask the billing staff which way yours is being submitted.

About this page

Written and reviewed by Alison Bays, MD, MPH, board-certified rheumatologist. Figures are current for 2026 and were last checked in August 2026.

This is educational information, not advice — not medical, legal, financial or insurance advice, and not a substitute for talking to your doctor or your plan. Nothing is sold here. No insurance is sold here, no plan is recommended, and neither this page nor its author is paid by any insurance company, plan, pharmaceutical manufacturer or broker. This page is not affiliated with, endorsed by, or connected to Medicare, the Centers for Medicare & Medicaid Services, or any government agency.

Found something wrong? Please tell us.